Authors:
Sharma, RA
McLelland, HR
Hill, KA
Ireson, CR
Euden, SA
Manson, MM
Pirmohamed, M
Marnett, LJ
Gescher, AJ
Steward, WP
Citation: Ra. Sharma et al., Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer, CLIN CANC R, 7(7), 2001, pp. 1894-1900
Authors:
Levitt, NC
Eskens, FALM
O'Byrne, KJ
Propper, DJ
Denis, LJ
Owen, SJ
Choi, L
Foekens, JA
Wilner, S
Wood, JM
Nakajima, M
Talbot, DC
Steward, WP
Harris, AL
Verweij, J
Citation: Nc. Levitt et al., Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer, CLIN CANC R, 7(7), 2001, pp. 1912-1922
Authors:
Sharma, RA
Ireson, CR
Verschoyle, RD
Hill, KA
Williams, ML
Leuratti, C
Manson, MM
Marnett, LJ
Steward, WP
Gescher, A
Citation: Ra. Sharma et al., Effects of dietary curcumin on glutathione S-transferase and malomdialdehyde-DNA adducts in rat liver and colon mucosa: Relationship with drug levels, CLIN CANC R, 7(5), 2001, pp. 1452-1458
Authors:
Sharma, RA
Manson, MM
Gescher, A
Steward, WP
Citation: Ra. Sharma et al., Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents, EUR J CANC, 37(1), 2001, pp. 12-22
Authors:
Thomas, AL
O'Byrne, K
Furber, L
Jeffery, K
Steward, WP
Citation: Al. Thomas et al., A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer, CANC CHEMOT, 48(4), 2001, pp. 266-268
Authors:
Sharma, RA
Eatock, MM
Twelves, CJ
Brown, G
McLelland, HR
Clayton, KT
O'Byrne, KJ
Moyses, C
Carmichael, J
Steward, WP
Citation: Ra. Sharma et al., Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver, CANC CHEMOT, 48(3), 2001, pp. 197-201
Authors:
Sharma, RA
Gescher, A
Plastaras, JP
Leuratti, C
Singh, R
Gallacher-Horley, B
Offord, E
Marnett, LJ
Steward, WP
Plummer, SM
Citation: Ra. Sharma et al., Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells, CARCINOGENE, 22(9), 2001, pp. 1557-1560
Authors:
Ireson, C
Orr, S
Jones, DJL
Verschoyle, R
Lim, CK
Luo, JL
Howells, L
Plummer, S
Jukes, R
Williams, M
Steward, WP
Gescher, A
Citation: C. Ireson et al., Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E-2 production, CANCER RES, 61(3), 2001, pp. 1058-1064
Citation: Al. Thomas et Wp. Steward, Marimastat: the clinical development of a matrix metalloproteinase inhibitor, EXPERT OP I, 9(12), 2000, pp. 2913-2922
Authors:
O'Byrne, KJ
Dalgleish, AG
Browning, MJ
Steward, WP
Harris, AL
Citation: Kj. O'Byrne et al., The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease, EUR J CANC, 36(2), 2000, pp. 151-169
Authors:
Thomas, AL
Cox, G
Sharma, RA
Steward, WP
Shields, F
Jeyapalan, K
Muller, S
O'Byrne, KJ
Citation: Al. Thomas et al., Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study, EUR J CANC, 36(18), 2000, pp. 2329-2334
Authors:
Cox, G
Walker, RA
Andi, A
Steward, WP
O'Byrne, KJ
Citation: G. Cox et al., Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer, LUNG CANC, 29(3), 2000, pp. 169-177
Authors:
Bramwell, VHC
Steward, WP
Nooij, M
Whelan, J
Craft, AW
Grimer, RJ
Taminau, AHM
Cannon, SR
Malcolm, AJ
Hogendoorn, PCW
Uscinska, B
Kirkpatrick, AL
Machin, D
Van Glabbeke, MM
Citation: Vhc. Bramwell et al., Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European osteosarcoma intergroup study, J CL ONCOL, 17(10), 1999, pp. 3260-3269